Catalyst Pharmaceuticals Inc’s filing revealed that its Chief Commercial Officer Del Carmen Jeffrey unloaded Company’s shares for reported $0.26 million on Nov 26 ’25. In the deal valued at $23.33 per share,10,983 shares were sold. As a result of this transaction, Del Carmen Jeffrey now holds 3,962 shares worth roughly $89620.44.
Then, Del Carmen Jeffrey bought 10,983 shares, generating $256,247 in total proceeds.
Before that, Elsbernd Brian bought 40,000 shares. Catalyst Pharmaceuticals Inc shares valued at $907,934 were divested by the Officer at a price of $22.70 per share.
Robert W. Baird initiated its Catalyst Pharmaceuticals Inc [CPRX] rating to an Outperform in a research note published on February 04, 2025; the price target was $28. A number of analysts have revised their coverage, including Stephens’s analysts, who began to cover the stock in mid November with a ‘”an Overweight”‘ rating. Citigroup began covering CPRX with “Buy” recommendation on March 14, 2024. BofA Securities started covering the stock on March 07, 2024. It rated CPRX as “a Buy”.
Price Performance Review of CPRX
On Tuesday, Catalyst Pharmaceuticals Inc [NASDAQ:CPRX] saw its stock fall -0.31% to $22.62. Over the last five days, the stock has lost -3.79%. Catalyst Pharmaceuticals Inc shares have risen nearly 1.25% since the year began. Nevertheless, the stocks have risen 8.39% over the past one year. While a 52-week high of $26.58 was reached on 06/09/25, a 52-week low of $19.05 was recorded on 09/25/25.
Levels Of Support And Resistance For CPRX Stock
The 24-hour chart illustrates a support level at 22.38, which if violated will result in even more drops to 22.15. On the upside, there is a resistance level at 22.89. A further resistance level may holdings at 23.17.
How much short interest is there in Catalyst Pharmaceuticals Inc?
A steep rise in short interest was recorded in Catalyst Pharmaceuticals Inc stocks on 2025-11-14, growing by 66125.0 shares to a total of 8.49 million shares. Yahoo Finance data shows the prior-month short interest on 2025-10-15 was 8.42 million shares. There was a rise of 0.78%, which implies that there is a positive sentiment for the stock.
The most recent change occurred on December 21, 2023 when Oppenheimer began covering the stock and recommended ‘”an Outperform”‘ rating along with a $30 price target.
